Cargando…

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer

Histone acetylation is a critical process in the regulation of chromatin structure and gene expression. Histone deacetylases (HDACs) remove the acetyl group, leading to chromatin condensation and transcriptional repression. HDAC inhibitors are considered a new class of anticancer agents and have bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Danqi, Shen, Aijun, Fang, Guanghua, Liu, Hongchun, Zhang, Minmin, Tang, Shuai, Xiong, Bing, Ma, Lanping, Geng, Meiyu, Shen, Jingkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724696/ https://www.ncbi.nlm.nih.gov/pubmed/26904403 http://dx.doi.org/10.1016/j.apsb.2015.11.002

Ejemplares similares

FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
por: Zhang, Liping, et al.
Publicado: (2015)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
por: Sahu, Gautam K, et al.
Publicado: (2011)

Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells
por: Andrade, F.O., et al.
Publicado: (2012)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
por: Sun, Jingya, et al.
Publicado: (2018)

Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type‐A Receptor 5 Kinases in Hepatocellular Carcinoma
por: Wang, Xin, et al.
Publicado: (2018)

Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells
por: Alao, John P, et al.
Publicado: (2006)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

Facile Synthesis of 3-Substituted Thiazolo[2,3-α]tetrahydroisoquinolines
por: Huang, Sheng-Han, et al.
Publicado: (2021)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors
por: Zhang, Zhen, et al.
Publicado: (2016)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors
por: Shen, Fangzhou, et al.
Publicado: (2019)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression
por: Hu, Zonglong, et al.
Publicado: (2023)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

The effect of histone deacetylase inhibitors on AHSP expression
por: Okhovat, Mohammad Ali, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vgphf2q3vncir01jje7g5ekvmn